NCT04944654View on ClinicalTrials.gov

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 7, 2023

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

BIKTARVY 50Mg-200Mg-25Mg Tablet

Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg

Trial Locations (1)

SW10 0XD

Chelsea and Westminster Hospital NHS Foundation Trust, London

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Imperial College London

OTHER

lead

Chelsea and Westminster NHS Foundation Trust

OTHER